Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 8/20 | 0.36 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.34 |
| ▸ | USP7 | Q93009 | 2/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 5/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521237 | 0.84 | DHFR (0.43) | DHFRBACE1 | |
| SCHEMBL4524730 | 0.80 | RXRA (0.39) | — | |
| SCHEMBL4533682 | 0.78 | BACE1 (0.41) | DHFRBACE1 | |
| SCHEMBL4531646 | 0.72 | PTPN11 (0.33) | BACE1 | |
| SCHEMBL4532717 | 0.70 | CTSD (0.43) | BACE1 | |
| SCHEMBL9258765 | 0.69 | ERN1 (0.53) | CTSAOTUD7BDHFRCASR | |
| SCHEMBL16710320 | 0.69 | CTSA (0.47) | CTSACASR | |
| SCHEMBL4511419 | 0.69 | ALOX5AP (0.40) | DHFR | |
| SCHEMBL4525835 | 0.68 | CTSA (0.35) | CTSACASR | |
| SCHEMBL4528354 | 0.68 | ALOX5AP (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | claimed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | CTSA 1908/4885OTUD7B 439/4885USP7 1671/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | CTSA 1908/4885OTUD7B 439/4885USP7 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.